Gene Therapy

Gene therapy is a mostly experimental technique that uses genes to treat or prevent disease. It was first developed in 1972 but so far has had limited success. When perfected, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells to counteract a malfunctioning gene instead of using drugs or surgery.

Although gene therapy is a promising treatment option for a number of diseases (inherited disorders, types of cancer and certain viral infections), it remains risky. It is primarily being tested on diseases that have no other treatments. The term itself is somewhat fluid and is sometimes used to refer to gene editing and gene silencing. Researchers are taking several approaches, including:

  • Introducing a new gene into the body to help fight a disease
  • Replacing a mutated gene that causes disease with a healthy cope of the gene (also called ‘gene editing’)
  • Inactivating, or “knocking out,” a mutated gene that is functioning improperly (also called ‘gene silencing’)
How does gene therapy work?

Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.

A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they can't cause disease when used in people.

A variety of types of gene therapy products include:

  • Plasmid DNA: Circular DNA molecules can be genetically engineered to carry therapeutic genes into human cells.
  • Viral vectors: Viruses have a natural ability to deliver genetic material into cells, and therefore some gene therapy products are derived from viruses. Once viruses have been modified to remove their ability to cause infectious disease, these modified viruses can be used as vectors (vehicles) to carry therapeutic genes into human cells.
  • Bacterial vectors: Bacteria can be modified to prevent them from causing infectious disease and then used as vectors (vehicles) to carry therapeutic genes into human tissues.
  • Human gene editing technology: The goals of gene editing are to replace harmful genes or to repair mutated genes.
  • Patient-derived cellular gene therapy products: Cells are removed from the patient, genetically modified (often using a viral vector) and then returned to the patient.
What disorders have been or might be soon treated with gene therapy?

Hundreds of clinical trials are underway studying the technology’s potential use in a wide range of genetic disorders, cancer and HIV/AIDS. There is some debate over whether or not the US already has approved its first gene therapy treatment.

In August 2017, the Food and Drug Administration (FDA) approved a cancer therapy—a CAR-T treatment marketed as Kymriah—that uses a patient’s own T cells and is a variation of the gene therapy that is being developed to treat single-gene diseases. The T cells are extracted and genetically altered so that they have a new gene that codes for a protein, known as a chimeric antigen receptor (CAR), that is a hybrid of two immune system proteins. One part guides the cells to the cancer cell targets and the other alerts the immune system. The cells, programmed to target and kill leukemia cells, are then injected back into the patient. Another CAR-T treatment, marketed as Yescarta, was approved for adults with aggressive forms of non-Hodgkin’s lymphoma in October 2017.

Some in the scientific community have pushed back against the idea of calling Kymriah or Yescarta true gene therapies, since they don’t actually repair or replace a deficient gene. Instead, they say the most likely candidate to gain the first US approval is Luxturna, a one-time treatment that targets a rare, inherited form of blindness. A key committee of independent experts voted unanimously in October 2017 to recommend approval by the FDA for the treatment developed by Spark Therapeutics. The FDA is not bound by the panel’s decision, though the agency traditionally acts on its recommendations.

Hundreds of research studies (clinical trials) are underway to test gene therapies as treatments for genetic conditions, cancer and HIV/AIDS. ClinicalTrials.gov, a service of the National Institutes of Health, provides easy access to information about clinical trials. There is also a list of gene therapy clinical trials that are accepting (or will accept) participants. Among the studies and research:

  • A 7-year-old boy whose outer skin layer was nearly gone due to a genetic disease had it replaced, using his own genetically-modified stem cells, according to researchers from Germany, Austria and Italy reporting in Nature in November, 2017. He is now 9 and the doctored stem cells appear to be doing their jobs. The gene therapy, done in an emergency operation to save his life, could conceivably be used to treat other people with junctional epidermolysis bullosa (JEB).
  • Doctors successfully treated 15 babies who had spinal muscular atrophy type 1 (SMA1), a disease that gradually paralyzes babies and typically results in death by the age of 2. The treatment, reported in the New England Journal of Medicine, used a virus to carry the therapeutic gene through the bloodstream to the brain. That it was able to cross the so-called brain-blood barrier was a notable achievement, suggesting that scientists may be able to access the central nervous system easier than previously thought.
Why are gene therapy treatments so expensive?

The companies argue that their treatments, while expensive, can be considered a bargain when compared against the lifetime medical costs related to the diseases that are being treated. To that end, MIT Technology Review looked at the medical costs for several diseases being targeted. The lifetime costs for a 45-year-old with sickle cell disease was nearly $1 million; annual treatments for men with hemophilia cost $150,000; and the treatment for severe combined immune deficiency could top $4 million.

One of the factors in the equation is the desire by companies to recover research costs and turn a profit for investors. That’s a particular challenge when it comes to treating rare diseases, such as the immune deficiency disorder targeted by Strimvelis, a therapy with a price tag above $650,000. According to StatNews: “Despite its high cost, Strimvelis is unlikely to be a blockbuster for GSK. The disease it treats affects only about 15 people each year in Europe, according to the company. In the US, where GSK intends to seek approval next year, that number is closer to 12.”

Still, there are no guarantees the market will bear the costs of these treatments. The first gene therapy to be approved in Europe was Glybera, designed to treat lipoprotein lipase deficiency (a form of pancreatitis). The drug ended up being scrapped after insurers and health agencies refused to pay the $1 million price tag. Inventor UniQure abandoned plans to seek US approval for the treatment.

What are the ethical and religious challenges of gene therapy?

Because gene therapy involves making changes to the body’s set of basic instructions, it raises many unique societal concerns. The ethical questions surrounding gene therapy include:

  • Who decides which traits are normal and which constitute a disability or disorder?
  • Will the high costs of gene therapy make it available only to the wealthy?
  • Could the widespread use of gene therapy make society less accepting of people who are different or have issues treatable by gene therapy but are unable to afford it?
  • Should people be allowed to use gene therapy to enhance basic human traits such as height, intelligence or athletic ability?

The World Anti-Doping Agency (WADA) has banned gene therapy since 2003 (and has extended its ban to gene editing) “if [these techniques] have the potential to increase performance.” This is called somatic gene therapy, which transfers DNA to cells that do not produce sperm or eggs (somatic cells). There is a clear distinction between somatic cells, those making up almost all of the body, and germline cells, which are the eggs and sperm and the cells that produce them. Somatic gene therapy cannot be passed to a person’s children.

The more controversial use of gene therapy is what is called germline editing—the transfer of a section of DNA to cells that produce eggs or sperm and could be passed to future generations. While germline gene therapy could spare future generations in a family from having a particular genetic disorder, it could conceivably impact the development of a fetus in unexpected ways or have long-term side effects that are not yet known, although the extent of those potential differences is fiercely debated. Those who would be affected by germline gene therapy are not yet born, so they can’t choose whether to have the treatment. Because of these ethical concerns, the government does not allow federal funds to be used for research on germline gene therapy in people.

How is gene therapy regulated?

Because of the regulatory and scientific challenges surrounding gene therapy, the technology may become prohibitively expensive for patients other than those participating in clinical trials, which typically do not charge patients. And because the techniques are relatively new, some of the risks may be unpredictable.

The FDA regulates all gene therapy products in the United States and oversees research in this area. Those who wish to test an approach in a clinical trial must first obtain permission from the FDA, which has the authority to reject or suspend clinical trials that are suspected of being unsafe for participants. In November 2017, the FDA announced that it will speed up its review process for promising gene therapy treatments.

The National Institutes of Health (NIH) provides guidelines for investigators and institutions (such as universities and hospitals) to follow when conducting gene therapy clinical trials. These guidelines state that clinical trials at institutions receiving NIH funding for this type of research must be reviewed by the NIH Recombinant DNA Advisory Committee (RAC) to determine whether the work raises medical, ethical or safety issues that warrant further discussion at one of the RAC's public meetings. Multiple levels of additional evaluation and oversight ensure that safety concerns are a top priority in the planning and carrying out of gene therapy research.

Below is the complete archive of related articles sorted by date.

Refine Search in GLP Library
Fighting infectious diseases with immunotherapy on 'cusp of commercialization'

Fighting infectious diseases with immunotherapy on ‘cusp of commercialization’

Immunotherapy, which involves adapting immune cells to destroy specific cellular targets, has made a name for itself treating cancer. But ...
Hemophilia 12/7/17

Gene therapy could be ‘ideal cure’ for hemophilia B

[L]ast year, [Jay] Konduros enrolled in a clinical trial, receiving an experimental gene therapy at Children's Hospital of Philadelphia [to ...
DIY gene therapy? FDA is not a fan

DIY gene therapy? FDA is not a fan

A few biohackers (fans of do-it-yourself (DIY) science experiments) recently designed a gene therapy for HIV. Not only that, they posted a video ...
Exorbitant costs of gene therapy raise payment concerns for patients and government

Exorbitant costs of gene therapy raise payment concerns for patients and government

[Editor's note: Executives from several companies developing gene therapies gathered for a panel discussion at the recent Forbes Healthcare Summit, ...
Genetic engineering, synthetic biology poised to boost photosynthesis and carbon capture

Genetic engineering, synthetic biology poised to boost photosynthesis and carbon capture

In a feature article published in the open access journal eLife, an international team of experts led by Dr Bonnie Wintle ...
Can we solve the patent issues that threaten CRISPR research?

Can we solve the patent issues that threaten CRISPR research?

[Editor's note: Lawrence Horn is President and CEO of MPEG LA, which provides licenses for standards and other technology platforms.] Although recent ...
Insecticide resistance threatens to derail malaria control in Africa

Insecticide resistance threatens to derail malaria control in Africa

The largest genetic study of mosquitoes has found their ability to resist insecticides is evolving rapidly and spreading across Africa, ...
Why life-saving gene therapy isn't available yet to children who need it most

Why life-saving gene therapy isn’t available yet to children who need it most

[The first patient to permanently edit his DNA,] Brian Madeux, 44, of Arizona, is part of a clinical trial testing ...
Gene therapy challenge: Overcoming shortage of key and expensive viruses

Gene therapy challenge: Overcoming shortage of key and expensive viruses

Eager to speed development of revolutionary treatments, the Food and Drug Administration recently announced that it would expedite approval of ...
How gene therapy could help fight methamphetamine addiction

How gene therapy could help fight methamphetamine addiction

Gene therapy, which modifies a person’s DNA, has long been thought of as a way to treat genetic diseases—and, more recently, ...
Exploring national security risks related to gene editing

Exploring national security risks related to gene editing

Technology is advancing exponentially and the exciting field of genome editing is no exception. Scientists at the University of Wisconsin-Madison ...
Viewpoint: Cost of gene therapy could put experimental treatments out of reach for most

Viewpoint: Cost of gene therapy could put experimental treatments out of reach for most

Drugs that modify human genes have the potential to cure intractable diseases with just one treatment. Few could disagree that's ...
Canadian researchers can't use CRISPR in human embryo research

Canadian researchers can’t use CRISPR in human embryo research

In the United States, using genetic engineering techniques such as CRISPR to make genetic alterations that can be passed on ...
FDA details risk-based cellular therapy and regenerative medicine guidelines

FDA details risk-based cellular therapy and regenerative medicine guidelines

The FDA has issued two final guidances and two draft guidances, all designed to articulate the agency’s approach to developing ...
Talking Biotech: Pet dogs with genetic diseases testing ground for gene therapy

Talking Biotech: Pet dogs with genetic diseases testing ground for gene therapy

Journalist Emily Mullin: Gene therapies becoming more promising but restricted in humans because of safety concerns, prompting some researchers to ...
New T-cell treatment shows promise for treating leukemia

New T-cell treatment shows promise for treating leukemia

A new way of genetically altering a patient’s cells to fight cancer has helped desperately ill people with leukemia when ...
Gene therapy boost: FDA positions for faster reviews of new treatments

Gene therapy boost: FDA positions for faster reviews of new treatments

The Food and Drug Administration on [November 16] issued new guidelines to speed the introduction of treatments involving human cells ...
FDA likely to approve hereditary blindness gene therapy

FDA likely to approve hereditary blindness gene therapy

[A]nother gene therapy is on the cusp of approval, this time to treat a form of hereditary blindness. If given ...
A gene-editing first: Scientists try to edit a living human's DNA

A gene-editing first: Scientists try to edit a living human’s DNA

Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change ...
Ethical debates swirl around gene-editing decisions

Ethical debates swirl around gene-editing decisions

[Editor's note: Joselin Linder is the author of the book "The Family Gene: A Mission to Turn My Deadly Inheritance ...
The quest to make CRISPR gene editing as easy as a smartphone app

The quest to make CRISPR gene editing as easy as a smartphone app

[Biohacker Josiah Zayner] lives and works in Oakland, California, where he's converted a house into a scientific lab. Here, he ...
New error-free DNA sequencing method could diagnose rare diseases

New error-free DNA sequencing method could diagnose rare diseases

A virtually error-free new method of DNA sequencing could one day be used to diagnose extremely rare cancers and hereditary ...
Genetic Literacy Project’s Top 6 Stories for the Week – Nov. 13, 2017

Genetic Literacy Project’s Top 6 Stories for the Week – Nov. 13, 2017

USDA scraps overhaul of GMO and gene edited crop regulations that biotech advocates viewed as ‘unscientific’ | Paul McDivitt Gene therapy ...
Gene therapy creates boy's replacement skin from his stem cells

Gene therapy creates boy’s replacement skin from his stem cells

Doctors treated a 7-year-old boy’s devastating genetic skin disease—junctional epidermolysis bullosa—by genetically modifying his stem cells to create a new ...
What's the excitement over gene therapy?

What’s the excitement over gene therapy?

Gene therapy has been in the news a lot of late as a potential cure for a variety of genetic ...
Safer CRISPR? Cas13 version edits RNA, not DNA

Safer CRISPR? Cas13 version edits RNA, not DNA

CRISPR, while a major leap forward in gene editing, can still be a blunt instrument. There have been problems with ...
Fighting malaria: Bacteria targets parasites in mosquito gut

Fighting malaria: Bacteria targets parasites in mosquito gut

Using a bacteria strain that colonizes the mosquito digestive tract and spreads rapidly throughout the populations, scientists have successfully inhibited ...
Biohackers help 'patient' inject himself with experimental HIV treatment—live on Facebook

Biohackers help ‘patient’ inject himself with experimental HIV treatment—live on Facebook

[Tristan] Roberts is about to inject himself with an experimental gene therapy for HIV, a DIY prototype treatment designed by ...